Active Biotech (Stockholm: ACTI.ST) has presented clinical results for its ANYARA project at the major ASCO annual conference (42nd American Society for Clinical Oncology Annual Meeting, June 2 - 6 2006, www.asco.org). At the conference, Active Biotech presented interim data from the ongoing Phase I study of ANYARA for the treatment of advanced non-small cell lung, renal cell and pancreatic cancer.
